<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634113</url>
  </required_header>
  <id_info>
    <org_study_id>205.443</org_study_id>
    <secondary_id>2011-005512-28</secondary_id>
    <nct_id>NCT01634113</nct_id>
  </id_info>
  <brief_title>Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma</brief_title>
  <official_title>A Phase II/III, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution (2.5 µg and 5 µg) Administered Once Daily in the Afternoon Via Respimat® Inhaler for 12 Weeks in Patients 1 to 5 Years Old With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate the safety and efficacy of two doses of
      tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the
      afternoon in patients (1 to 5 years old) with persistent asthma on top of inhaled
      corticosteroid (ICS) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly Mean Combined Daytime Asthma Symptom Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period.
The PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days.
The combined daytime score is the average of scores from questions 4 - 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst).
The measured values presented are adjusted means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 Peak (0-3h) Change From Baseline</measure>
    <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
    <description>Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Overnight Asthma Symptom Score Response</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period.
The overnight score is the score from the following question in the PACD, &quot;How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?&quot;. This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received β-Agonist at least one time since he/she went to bed. A week was defined as 7 days.
Scores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown.
The measured values presented are adjusted means</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Percentage of Days Without Asthma Symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weekly Percentage of days without asthma symptoms at week 12.
A day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor's office, emergency department, or hospital. A week was defined as 7 days.
The measured values presented are adjusted means</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Nighttime Awakenings Due to Asthma Symptoms</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period.
The weekly mean was calculated as the average of the weekly scores for the question &quot;Did your child wake up during the night due to his/her asthma?&quot; The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days.
The measured values presented are adjusted means</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC (0-3h) Change From Baseline</measure>
    <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
    <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Change From Baseline</measure>
    <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
    <description>Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0-3h)) after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC (0-3h) Change From Baseline</measure>
    <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
    <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1 Measurements</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FVC Measurements</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in individual FVC measurements at each timepoint after 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, delivered with Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, delivered with Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily, delivered with Respimat® inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium-bromide</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium-bromide</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching tiotropium</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients' parents (or legal guardians) must sign and date an informed consent
             consistent with ICH-GCP guidelines and local legislation prior to participation in the
             trial. Where appropriate, participants should assent to enroll in the study.

          2. Male or female patients between 1 and 5 years of age.

          3. By a physician documented (at least 6 month) history of persistent asthma symptoms,
             including (but not limited to) wheezing, cough, and/or shortness of breath.
             (persistent = need for inhalation corticosteroid maintenance therapy to control asthma
             symptoms)

          4. For patients aged 5 years and capable of performing technically acceptable Pulmonary
             Function tests (PFTs): documented impaired lung function (i.e. pre-bronchodilator
             Forced Expiratory Volume in 1 second (FEV1) is smaller or equal to 90% of predicted
             normal).

          5. All patients must have been on maintenance treatment with an inhaled corticosteroid at
             stable dose, either as mono treatment or in combination with another controller
             medication, for at least 4 weeks before Visit 1.

          6. All patients must be symptomatic (partly controlled) as defined by the Global
             Initiative for Asthma (GINA) guideline for children aged 5 years and younger in the
             week prior to Visit 1 (screening) and in the week prior to randomisation (Visit 2).

        Further inclusion criteria apply.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.

          2. Patients with clinically relevant abnormal screening haematology or blood chemistry
             will be excluded if the abnormality defines a significant disease as defined in
             exclusion criterion 1.

          3. Patients with a history of congenital or acquired heart disease, or patients who have
             been hospitalised for cardiac syncope or failure during the past year.

          4. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac
             arrhythmia requiring intervention (e.g. pacemaker implantation) or a change in drug
             therapy within the past year.

          5. Patients with a malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy.

          6. Patients with clinically significant lung diseases other than asthma.

          7. Alternative causes (other causes than asthma) that can lead to respiratory symptoms of
             wheeze, cough and shortness of breath.

          8. Patients with known active tuberculosis.

          9. Patients who have undergone thoracotomy with pulmonary resection.

         10. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit
             1).

        Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.443.12003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.12005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.12006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.12004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.03003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.03001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.03002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.03010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guri</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.05001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balvi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.05003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rezekne</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.05002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.06002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.06003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pahang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.04003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.04001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.09001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.09002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.443.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Philippines</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <results_first_submitted>June 3, 2015</results_first_submitted>
  <results_first_submitted_qc>June 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2015</results_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="P2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="P3">
          <title>Tio R5</title>
          <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all randomised patients who received at least one dose of trial medication</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="B2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="B3">
          <title>Tio R5</title>
          <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="1.4"/>
                    <measurement group_id="B2" value="3.1" spread="1.5"/>
                    <measurement group_id="B3" value="3.1" spread="1.3"/>
                    <measurement group_id="B4" value="3.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weekly Mean Combined Daytime Asthma Symptom Score</title>
        <description>Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period.
The PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days.
The combined daytime score is the average of scores from questions 4 – 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst).
The measured values presented are adjusted means.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set, which included all randomised patients who received at least one dose of trial medication, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Combined Daytime Asthma Symptom Score</title>
          <description>Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period.
The PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days.
The combined daytime score is the average of scores from questions 4 – 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst).
The measured values presented are adjusted means.</description>
          <population>Full analysis set, which included all randomised patients who received at least one dose of trial medication, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.456" spread="0.084"/>
                    <measurement group_id="O2" value="-0.535" spread="0.082"/>
                    <measurement group_id="O3" value="-0.504" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4963</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.312</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6936</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.123</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.292</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Peak (0-3h) Change From Baseline</title>
        <description>Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12</description>
        <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak (0-3h) Change From Baseline</title>
          <description>Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" spread="0.026"/>
                    <measurement group_id="O2" value="0.130" spread="0.125"/>
                    <measurement group_id="O3" value="0.145" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Overnight Asthma Symptom Score Response</title>
        <description>Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period.
The overnight score is the score from the following question in the PACD, &quot;How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?&quot;. This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received β-Agonist at least one time since he/she went to bed. A week was defined as 7 days.
Scores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown.
The measured values presented are adjusted means</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Overnight Asthma Symptom Score Response</title>
          <description>Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period.
The overnight score is the score from the following question in the PACD, &quot;How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?&quot;. This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received β-Agonist at least one time since he/she went to bed. A week was defined as 7 days.
Scores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown.
The measured values presented are adjusted means</description>
          <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.671" spread="0.110"/>
                    <measurement group_id="O2" value="-0.588" spread="0.111"/>
                    <measurement group_id="O3" value="-0.655" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5995</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.157</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.229</ci_lower_limit>
            <ci_upper_limit>0.394</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9251</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.160</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.303</ci_lower_limit>
            <ci_upper_limit>0.333</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Percentage of Days Without Asthma Symptoms</title>
        <description>Weekly Percentage of days without asthma symptoms at week 12.
A day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor’s office, emergency department, or hospital. A week was defined as 7 days.
The measured values presented are adjusted means</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Percentage of Days Without Asthma Symptoms</title>
          <description>Weekly Percentage of days without asthma symptoms at week 12.
A day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor’s office, emergency department, or hospital. A week was defined as 7 days.
The measured values presented are adjusted means</description>
          <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.151" spread="7.405"/>
                    <measurement group_id="O2" value="55.401" spread="7.181"/>
                    <measurement group_id="O3" value="50.654" spread="7.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8279</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.250</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.324</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.243</ci_lower_limit>
            <ci_upper_limit>22.743</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8181</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.497</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.826</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.987</ci_lower_limit>
            <ci_upper_limit>18.994</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication</title>
        <description>Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication</title>
          <description>Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.</description>
          <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.94" spread="36.80"/>
                    <measurement group_id="O2" value="24.23" spread="36.86"/>
                    <measurement group_id="O3" value="24.88" spread="38.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Nighttime Awakenings Due to Asthma Symptoms</title>
        <description>Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period.
The weekly mean was calculated as the average of the weekly scores for the question “Did your child wake up during the night due to his/her asthma?” The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days.
The measured values presented are adjusted means</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Nighttime Awakenings Due to Asthma Symptoms</title>
          <description>Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period.
The weekly mean was calculated as the average of the weekly scores for the question “Did your child wake up during the night due to his/her asthma?” The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days.
The measured values presented are adjusted means</description>
          <population>Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.318" spread="0.080"/>
                    <measurement group_id="O2" value="-0.257" spread="0.078"/>
                    <measurement group_id="O3" value="-0.392" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5869</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.112</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.161</ci_lower_limit>
            <ci_upper_limit>0.283</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5230</p_value>
            <p_value_desc>All treatment comparisons were exploratory, no formal hypothesis testing was performed.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.305</ci_lower_limit>
            <ci_upper_limit>0.156</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Change From Baseline</title>
        <description>Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Change From Baseline</title>
          <description>Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.032"/>
                    <measurement group_id="O2" value="0.017" spread="0.108"/>
                    <measurement group_id="O3" value="0.085" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC (0-3h) Change From Baseline</title>
        <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0–3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).</description>
        <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC (0-3h) Change From Baseline</title>
          <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0–3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="0.043"/>
                    <measurement group_id="O2" value="0.072" spread="0.114"/>
                    <measurement group_id="O3" value="0.077" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Change From Baseline</title>
        <description>Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0–3h)) after 12 weeks of treatment.</description>
        <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Change From Baseline</title>
          <description>Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0–3h)) after 12 weeks of treatment.</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.210" spread="0.054"/>
                    <measurement group_id="O2" value="0.136" spread="0.143"/>
                    <measurement group_id="O3" value="0.060" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Change From Baseline</title>
        <description>Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Change From Baseline</title>
          <description>Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.155" spread="0.060"/>
                    <measurement group_id="O2" value="-0.027" spread="0.133"/>
                    <measurement group_id="O3" value="-0.050" spread="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC (0-3h) Change From Baseline</title>
        <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0–3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).</description>
        <time_frame>10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC (0-3h) Change From Baseline</title>
          <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0–3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="0.037"/>
                    <measurement group_id="O2" value="0.035" spread="0.105"/>
                    <measurement group_id="O3" value="0.003" spread="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual FEV1 Measurements</title>
        <description>Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual FEV1 Measurements</title>
          <description>Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time: 0 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.03"/>
                    <measurement group_id="O2" value="0.02" spread="0.11"/>
                    <measurement group_id="O3" value="0.09" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.09"/>
                    <measurement group_id="O2" value="0.03" spread="0.13"/>
                    <measurement group_id="O3" value="0.12" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.08"/>
                    <measurement group_id="O2" value="0.10" spread="0.13"/>
                    <measurement group_id="O3" value="0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.05"/>
                    <measurement group_id="O2" value="0.09" spread="0.13"/>
                    <measurement group_id="O3" value="0.04" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.05"/>
                    <measurement group_id="O2" value="0.06" spread="0.13"/>
                    <measurement group_id="O3" value="0.05" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual FVC Measurements</title>
        <description>Change from baseline in individual FVC measurements at each timepoint after 12 weeks</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual FVC Measurements</title>
          <description>Change from baseline in individual FVC measurements at each timepoint after 12 weeks</description>
          <population>Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time: 0 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.06"/>
                    <measurement group_id="O2" value="-0.03" spread="0.13"/>
                    <measurement group_id="O3" value="-0.05" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.07"/>
                    <measurement group_id="O2" value="0.04" spread="0.15"/>
                    <measurement group_id="O3" value="0.06" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.04"/>
                    <measurement group_id="O2" value="0.06" spread="0.14"/>
                    <measurement group_id="O3" value="0.05" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.04"/>
                    <measurement group_id="O2" value="0.02" spread="0.10"/>
                    <measurement group_id="O3" value="-0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time: 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.07"/>
                    <measurement group_id="O2" value="0.04" spread="0.13"/>
                    <measurement group_id="O3" value="-0.03" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug intake until 30 days after last drug intake, up to 119 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="E2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="E3">
          <title>Tio R5</title>
          <description>Inhalation of 5μg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

